Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy

Antiviral Therapy

Volumn 15, Issue 2, 2010, Pages 145-155

  Lui, Yanni Yan Ni ^a   Tsoi, Kelvin Kam Fai ^a   Wong, Vincent Wai Sun ^a   Kao, Jia Horng ^b   Hou, Jin Lin ^c   Teo, Eng Kiong ^d   Mohamed, Rosmawati ^e   Piratvisuth, Teerha ^f   Han, Kwang Hyub ^g   Mihm, Ulrike ^h   Wong, Grace Lai Hung ^a   Chan, Henry Lik Yuen ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

^d CHANGI GENERAL HOSPITAL   (Singapore)

^e UNIVERSITY OF MALAYA   (Malaysia)

^f PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^g Yonsei University College of Medicine   (South Korea)

^h UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ADD ON THERAPY; ARTICLE; ASIA; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; GERMANY; HEALTH CARE COST; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MARKET; MODEL; MONEY; PRIORITY JOURNAL; UNITED STATES;

ADENINE; ANTIVIRAL AGENTS; ASIA; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GERMANY; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MODELS, ECONOMIC; NUCLEOSIDES; PHOSPHONIC ACIDS; PYRIMIDINONES; SALVAGE THERAPY; TREATMENT OUTCOME; UNITED STATES;

EID: 77950670544     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1496     Document Type: Article

References (36)

1. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507-539.
2. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2:263-283.
3. Chan HL, Sung JJ. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 2006; 26:153-161.
4. 4. Alter MJ, Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994; 23:437-455. (Pubitemid 24283692)
5. 5. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73. (Pubitemid 43042691)
6. 6. Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006; 101:1797-1803. (Pubitemid 44166589)
7. Chan HL, Tse CH, Mo F, et al. High viral load and hepatitis B virus subgenotype Ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol 2008; 26:177-182.
8. Iloeje UH, Yang HI, Su J, et al. HBV viral load less than 10,000 copies/ml is associated with significant risk of hepatocellular carcinoma in chronic hepatitis B (CHB) patients: an update from the R.E.V.E.A.L.-HBV study. 58th Annual Meeting of the American Association for the Study of Liver Diseases. 2-6 November 2007, Boston, MA, USA. Abstract 907.
9. 9. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130:678-686. (Pubitemid 43374518)
10. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351:1521-1531.
11. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50:227-242.
12. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chornic hepatitis B. N Engl J Med 2007; 357:2576-2588.
13. Di Bisceglie AM, Lai CL, Gane E, et al. Telbivudine GLOBE trial: maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients. 57th Annual Meeting of the American Association for the Study of Liver Diseases. 27-31 October 2006, Boston, MA, USA. Abstract 112.
14. Zeuzem S, Gane E, Liaw YF, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009; 51:11-20.
15. Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136:486-495.
16. Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007; 5:890-897.
17. Veenstra DL, Sullivan SD, Clarke 1, et al. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. Pharmacoeconomics 2007; 25:963-977.
18. Spackman DE, Veenstra DL. A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B. Pharmacoeconomics 2008; 26:937-949.
19. 19. Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BM. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med 2005; 142:821-831. (Pubitemid 40664041)
20. Lacey l, Chien RN, Chuang WL, Pwu RF. Economie evaluation of chronic hepatitis B treatments in Taiwan. J Gastroenterol Hepatol 2008; 23:571-579.
21. 21. Lacey LF, Gane E. The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore. J Viral Hepat 2007; 14:751-766. (Pubitemid 47561579)
22. 22. Chan HL, Hui AY, Wong VW, Chim AM, Wong ML, Sung JJ. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology 2005; 41:1357-1364. (Pubitemid 40770289)
23. Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon α-2b. Gastroenterology 2008; 135:459-467.
24. Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004; 19:1276-1282.
25. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6:1315-1341.
26. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125:1714-1722.
27. 27. van Bommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudineresistant hepatitis B virus infection. Hepatology 2004; 40:1421-1425. (Pubitemid 39657017)
28. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119:172-180.
29. Heathcote EJ, Gane EJ, deMan RA, et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B (study 103), preliminary analysis. 59th Annual Meeting of the American Association for the Study of Liver Diseases. 30 October-3 November 2008, Boston, MA, USA. Abstract 158.
30. Marcellin P, Buti M, Krastev Z, et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-negative patients with chronic hepatitis B (study 102), preliminary analysis. 59th Annual Meeting of the American Association for the Study of Liver Diseases. 30 October-3 November 2008, Boston, MA, USA. Abstract 146.
31. Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133:1437-1444.
32. Yao G, Chen C, Lu W, et al. Efficacy and safety of entecavir compared to lamivudine in nucleoside-naive patients with chronic hepatitis B: a randomized double-blind trial in China. Hepatol Int 2007; 1:365-372.
33. Shouval D, Lai C, Chang T, et al. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discountinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol 2009; 50:289-295.
34. Han SH, Lai CL, Gane E, et al. Telbivudine GLOBE trial at year two: efficacy, safety, and predictors of outcome in patients with chronic hepatitis B. Digestive Disease Week 2007; 2007:19-24.
35. Zeuzem S, Lai CL, Gane E, et al. Optimal virologie and clinical efficacy at one year is associated with maximal early HBV suppression in nucleoside-treated hepatitis B patients. 41st Annual Meeting of the European Association for the Study of the Liver. 26-30 April 2006, Vienna, Austria. Abstract 51.
36. Rxzone.us. Online Pharmacy (Accessed 15 November 2008.) Available from http://www.rxzone.us/